TGF-β induced TMEPAI/PMEPA1 inhibits canonical smad signaling through R-smad sequestration and promotes noncanonical PI3K/Akt signaling by reducing PTEN in triple negative breast cancer

Prajjal K. Singha, Srilakshmi Pandeswara, Hui Geng, Rongpei Lan, Manjeri A. Venkatachalam, Pothana Saikumar

Research output: Contribution to journalArticle

35 Scopus citations

Abstract

TMEPAI (transmembrane prostate androgen-induced) is amplified at genomic, transcript and protein levels in triple-negative breast cancers and promotes TGF-β dependent growth, motility and invasion. Tumor promotion by TMEPAI depends on two different but related actions on TGF-β signaling. Firstly, TMEPAI binds and sequesters regulatory Smads2/3 and thereby decreases growth suppressive signaling by TGF-β. Secondly, increased expression of TMEPAI decreases PTEN (phosphatase and tensin homolog) abundance, and thereby increases TGF-β dependent tumor promotive PI3K/Akt signaling. These actions of TMEPAI give rise to increased cell proliferation and motility. Moreover, signaling alterations produced by high TMEPAI were associated with oncogenic Snail expression and lung metastases. Finally, an inverse correlation between TMEPAI and PTEN levels was confirmed in triple negative breast cancer tumor samples. Together, our findings suggest that TMEPAI has dually critical roles to promote TGF-β dependent cancer cell growth and metastasis. Thus, redirected TGF-β signaling through TMEPAI may play a pivotal role in TGF-β mediated tumor promotion.

Original languageEnglish (US)
Pages (from-to)320-336
Number of pages17
JournalGenes and Cancer
Volume5
Issue number9-10
StatePublished - Jan 1 2014

Keywords

  • PMEPA1
  • PTEN
  • Smad
  • TGF-β
  • TMEPAI
  • Triple Negative Breast Cancer (TNBC)

ASJC Scopus subject areas

  • Genetics
  • Cancer Research

Fingerprint Dive into the research topics of 'TGF-β induced TMEPAI/PMEPA1 inhibits canonical smad signaling through R-smad sequestration and promotes noncanonical PI3K/Akt signaling by reducing PTEN in triple negative breast cancer'. Together they form a unique fingerprint.

  • Cite this